Sequence diversity of NanA manifests in distinct enzyme kinetics and inhibitor susceptibility

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Xu, Zhongli ^a   Von Grafenstein, Susanne ^b   Walther, Elisabeth ^a   Fuchs, Julian E ^b   Liedl, Klaus R ^b   Sauerbrei, Andreas ^a   Schmidtke, Michaela ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; LYASE; MUTANT PROTEIN; N-ACETYLNEURAMINATE LYASE;

AMINO ACID SUBSTITUTION; ANTAGONISTS AND INHIBITORS; DNA SEQUENCE; ENZYMOLOGY; GENETIC VARIATION; GENETICS; KINETICS; METABOLISM; MOLECULAR DOCKING; STREPTOCOCCUS PNEUMONIAE;

AMINO ACID SUBSTITUTION; ENZYME INHIBITORS; GENETIC VARIATION; KINETICS; MOLECULAR DOCKING SIMULATION; MUTANT PROTEINS; OXO-ACID-LYASES; SEQUENCE ANALYSIS, DNA; STREPTOCOCCUS PNEUMONIAE;

EID: 84964866066     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25169     Document Type: Article

References (54)

1. Huang, S. S. et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 29, 3398-3412, doi: 10.1016/j.vaccine.2011.02.088 (2011).
2. Simell, B. et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 11, 841-855, doi: 10.1586/Erv.12.53 (2012).
3. Adegbola, R. A. Childhood pneumonia as a global health priority and the strategic interest of the Bill & Melinda Gates Foundation. Clin Infect Dis 54 Suppl 2, S89-92, doi: 10.1093/cid/cir1051 (2012).
4. Kadioglu, A., Weiser, J. N., Paton, J. C. & Andrew, P. W. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 6, 288-301, doi: 10.1038/Nrmicro1871 (2008).
5. Bogaert, D., de Groot, R. & Hermans, P. W. M. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4, 144-154, doi: 10.1016/S1473-3099(04)00938-7 (2004).
6. Lofing, J., Vimberg, V., Battig, P. & Henriques-Normark, B. Cellular interactions by LPxTG-anchored pneumococcal adhesins and their streptococcal homologues. Cellular Microbiology 13, 186-197, doi: 10.1111/j.1462-5822.2010.01560.x (2011).
7. Taylor, G. Sialidases: Structures, biological signifcance and therapeutic potential. Curr Opin Struc Biol 6, 830-837, doi: 10.1016/S0959-440x(96)80014-5 (1996).
8. Tong, H. H., Blue, L. E., James, M. A. & DeMaria, T. F. Evaluation of the virulence of a Streptococcus pneumoniae neuraminidase-defcient mutant in nasopharyngeal colonization and development of otitis media in the chinchilla model. Infection and Immunity 68, 921-924 (2000).
9. King, S. J., Hippe, K. R. & Weiser, J. N. Deglycosylation of human glycoconjugates by the sequential activities of exoglycosidases expressed by Streptococcus pneumoniae. Mol Microbiol 59, 961-974, doi: 10.1111/j.1365-2958.2005.04984.x (2006).
10. Orihuela, C. J., Gao, G. L., Francis, K. P., Yu, J. & Tuomanen, E. I. Tissue-specifc contributions of pneumococcal virulence factors to pathogenesis. Journal of Infectious Diseases 190, 1661-1669, doi: 10.1086/424596 (2004).
11. Manco, S. et al. Pneumococcal neuraminidases A and B both have essential roles during infection of the respiratory tract and sepsis. Infection and Immunity 74, 4014-4020, doi:10.1128/IAI.01237-05 (2006).
12. Kelly, R. T., Farmer, S. & Greif, D. Neuraminidase Activities of Clinical Isolates of Diplococcus Pneumoniae. Journal of Bacteriology 94, 272-& (1967).
13. Pettigrew, M. M., Fennie, K. P., York, M. P., Daniels, J. & Ghafar, F. Variation in the presence of neuraminidase genes among Streptococcus pneumoniae isolates with identical sequence types. Infection and Immunity 74, 3360-3365, doi: 10.1128/Iai.01442-05 (2006).
14. Roggentin, P. et al. Conserved Sequences in Bacterial and Viral Sialidases. Glycoconjugate J 6, 349-353, doi: 10.1007/Bf01047853 (1989).
15. Xu, G. G. et al. Crystal Structure of the NanB Sialidase from Streptococcus pneumoniae. Journal of Molecular Biology 384, 436-449, doi: 10.1016/j.jmb.2008.09.032 (2008).
16. Connaris, H. et al. Prevention of infuenza by targeting host receptors using engineered proteins. Proc Natl Acad Sci USA 111, 6401-6406, doi: 10.1073/pnas.1404205111 (2014).
17. King, S. J., Whatmore, A. M. & Dowson, C. G. NanA, a neuraminidase from Streptococcus pneumoniae, shows high levels of sequence diversity, at least in part through recombination with Streptococcus oralis. Journal of Bacteriology 187, 5376-5386, doi: 10.1128/Jb.187.15.5376-5386.2005 (2005).
18. Straume, D., Stamsas, G. A. & Havarstein, L. S. Natural transformation and genome evolution in Streptococcus pneumoniae. Infect Genet Evol. doi: 10.1016/j.meegid.2014.10.020 (2014).
19. Trappetti, C. et al. Sialic acid: a preventable signal for pneumococcal bioflm formation, colonization, and invasion of the host. J Infect Dis 199, 1497-1505, doi: 10.1086/598483 (2009).
20. Parker, D. et al. The NanA Neuraminidase of Streptococcus pneumoniae Is Involved in Bioflm Formation. Infection and Immunity 77, 3722-3730 (2009).
21. Kim, C. U. et al. Infuenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-infuenza activity. J Am Chem Soc 119, 681-690 (1997).
22. VonItzstein, M. et al. Rational Design of Potent Sialidase-Based Inhibitors of Infuenza-Virus Replication. Nature 363, 418-423, doi: 10.1038/363418a0 (1993).
23. McCullers, J. A. Efect of antiviral treatment on the outcome of secondary bacterial pneumonia afer infuenza. J Infect Dis 190, 519-526, doi: 10.1086/421525 (2004).
24. Tanaka, A. et al. The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice. Antiviral therapy 20, 11-19, doi: 10.3851/IMP2744 (2015).
25. Gut, H., Xu, G. G., Taylor, G. L. & Walsh, M. A. Structural Basis for Streptococcus pneumoniae NanA Inhibition by Infuenza Antivirals Zanamivir and Oseltamivir Carboxylate. Journal of Molecular Biology 409, 496-503 (2011).
26. Walther, E. et al. Antipneumococcal activity of neuraminidase inhibiting artocarpin. Int J Med Microbiol 18, 00163-00165 (2014).
27. Tamura, K. et al. MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods. Mol Biol Evol 28, 2731-2739, doi: 10.1093/molbev/msr121 (2011).
28. Lanie, J. A. et al. Genome sequence of Avery's virulent serotype 2 strain D39 of Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain R6. J Bacteriol 189, 38-51, doi: 10.1128/Jb.01148-06 (2007).
29. Walther, E. et al. Antipneumococcal activity of neuraminidase inhibiting artocarpin. International journal of medical microbiology: IJMM 305, 289-297, doi: 10.1016/j.ijmm.2014.12.004 (2015).
30. Richter, M. et al. Complementary Assays Helping to Overcome Challenges for Identifying Neuraminidase Inhibitors. Future Virol 10, 77-88, doi: 10.2217/fvl.14.97 (2015).
31. Xu, G. G., Li, X. J., Andrew, P. W. & Taylor, G. L. Structure of the catalytic domain of Streptococcus pneumoniae sialidase NanA. Acta Crystallographica Section F-Structural Biology and Crystallization Communications 64, 772-775 (2008).
32. Fuchs, J. E. et al. Independent Metrics for Protein Backbone and Side-Chain Flexibility: Time Scales and Efects of Ligand Binding. J Chem Teory Comput 11, 851-860, doi: 10.1021/ct500633u (2015).
33. Brittan, J. L., Buckeridge, T. J., Finn, A., Kadioglu, A. & Jenkinson, H. F. Pneumococcal neuraminidase A: an essential upper airway colonization factor for Streptococcus pneumoniae. Molecular Oral Microbiology 27, 270-283 (2012).
34. Kadioglu, A., Weiser, J. N., Paton, J. C. & Andrew, P. W. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 6, 288-301, doi: 10.1038/nrmicro1871 (2008).
35. Johnston, C. et al. Natural genetic transformation generates a population of merodiploids in Streptococcus pneumoniae. PLos Genet 9, e1003819, doi: 10.1371/journal.pgen.1003819 (2013).
36. McCullers, J. A. & Bartmess, K. C. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 187, 1000-1009, doi: 10.1086/368163 (2003).
37. Burmeister, W. P., Cusack, S. & Ruigrok, R. W. H. Calcium Is Needed for the Termostability of Infuenza-B Virus Neuraminidase. J Gen Virol 75, 381-388, doi: 10.1099/0022-1317-75-2-381 (1994).
38. Crennell, S., Garman, E., Laver, G., Vimr, E. & Taylor, G. Crystal-Structure of Vibrio-Cholerae Neuraminidase Reveals Dual Lectin-Like Domains in Addition to the Catalytic Domain. Structure 2, 535-544, doi: 10.1016/S0969-2126(00)00053-8 (1994).
39. Hsiao, Y. S., Parker, D., Ratner, A. J., Prince, A. & Tong, L. Crystal structures of respiratory pathogen neuraminidases. Biochemical and Biophysical Research Communications 380, 467-471 (2009).
40. von Grafenstein, S. et al. Interface dynamics explain assembly dependency of infuenza neuraminidase catalytic activity. J Biomol Struct Dyn 33, 104-120, doi: 10.1080/07391102.2013.855142 (2015).
41. Brear, P., Telford, J., Taylor, G. L. & Westwood, N. J. Synthesis and structural characterisation of selective non-carbohydrate-based inhibitors of bacterial sialidases. Chembiochem 13, 2374-2383, doi: 10.1002/cbic.201200433 (2012).
42. Cheng, L. S. et al. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian infuenza neuraminidase. J Med Chem 51, 3878-3894, doi: 10.1021/jm8001197 (2008).
43. Russell, R. J. et al. The structure of H5N1 avian infuenza neuraminidase suggests new opportunities for drug design. Nature 443, 45-49, doi: 10.1038/nature05114 (2006).
44. von Grafenstein, S., Fuchs, J. E. & Liedl, K. R. In Application of Computational Techniques in Pharmacy and Medicine Vol. 17 Challenges and Advances in Computational Chemistry and Physics (eds Leonid Gorb, Victor Kuz'min & Eugene Muratov) Ch. 15, 501-538 (Springer Netherlands, 2014).
45. Wattanagoon, Y. et al. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Ch 53, 945-952, doi: 10.1128/AAC.00588-08 (2009).
46. Okomo-Adhiambo, M. et al. Detection of E119V and E119I Mutations in Influenza A (H3N2) Viruses Isolated from an Immunocompromised Patient: Challenges in Diagnosis of Oseltamivir Resistance. Antimicrob Agents Ch 54, 1834-1841, doi: 10.1128/Aac.01608-09 (2010).
47. Case, D. et al. AMBER12 and AMBERTOOLS13. San Francisco, CA: Universty of California San Francisco (2012).
48. Lindorf-Larsen, K. et al. Systematic validation of protein force felds against experimental data. PLos One 7, e32131, doi: 10.1371/journal.pone.0032131 (2012).
49. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 79, 926, doi: 10.1063/1.445869 (1983).
50. von Grafenstein, S. et al. Interface dynamics explain assembly dependency of infuenza neuraminidase catalytic activity. Journal of biomolecular structure & dynamics. doi: 10.1080/07391102.2013.855142 (2013).
51. Salomon-Ferrer, R., Case, D. A. & Walker, R. C. An overview of the Amber biomolecular simulation package. Wiley Interdisciplinary Reviews: Computational Molecular Science 3, 198-210, doi: 10.1002/wcms.1121 (2013).
52. Wallnoefer, H. G., Handschuh, S., Liedl, K. R. & Fox, T. Stabilizing of a Globular Protein by a Highly Complex Water Network: A Molecular Dynamics Simulation Study on Factor Xa. The Journal of Physical Chemistry B 114, 7405-7412, doi: 10.1021/jp101654g (2010).
53. Sgobba, M., Caporuscio, F., Anighoro, A., Portioli, C. & Rastelli, G. Application of a post-docking procedure based on MM-PBSA and MM-GBSA on single and multiple protein conformations. European Journal of Medicinal Chemistry 58 431-40, doi: 10.1016/j. ejmech.2012.10.024 (2012).
54. Miller, B. R. III et al. MMPBSA.py: An Efcient Program for End-State Free Energy Calculations. Journal of Chemical Teory and Computation 8 3314-3321, doi: 10.1021/ct300418h (2012).